© Copyright Acquisition International 2026 - All Rights Reserved.

Article Image - Evotec Announces Its Intent to Acquire Cyprotex Plc
Posted 26th October 2016

Evotec Announces Its Intent to Acquire Cyprotex Plc

Acquisition would add world-leading high-quality ADME-Tox services and strengthen Evotec's leadership in drug discovery

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Evotec Announces Its Intent to Acquire Cyprotex Plc
Image

Evotec Announces Its Intent to Acquire Cyprotex Plc

Acquisition would add world-leading high-quality ADME-Tox services and strengthen Evotec’s leadership in drug discovery

– Evotec will pay approximately £ 55.36 m (EUR 62.00 m) in cash for the full share capital of Cyprotex and funding of all existing debt of the AIM-listed company

– Proposed acquisition, unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that it has made an offer to acquire Cyprotex PLC (“Cyprotex”, AIM: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK. Cyprotex serves the industry’s increasing requirement for earlier drug screening, regulatory requirements and reducing the reliance on animal testing.

The proposed acquisition, which has been unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016. Evotec will pay approximately £ 55.36 m (EUR 62.00 m; £/EUR exchange rate of 1.12) in cash for the acquisition of all 26.1 million issued and to be issued Cyprotex shares and the funding of all existing company debt. The offer of 1.60 £ per Cyprotex share reflects a 9.4% premium to the VWAP of the past 30 trading days at AIM. The offer is intended to be implemented by a scheme of arrangement regulated by the UK takeover code, with already >50% shares secured irrevocable. The acquisition will add to Evotec’s revenues and be accretive to Evotec’s 2017 EBITDA.

Cyprotex is the world’s largest contract research organisation specialising in pre-clinical ADME-Tox and DMPK serving the Pharmaceutical, Chemical, Agrochemical and Cosmetics markets. Cyprotex, headquartered in the UK, was founded in 1999 and is publicly traded on AIM (CRX). It has 136 employees working from sites at Macclesfield and Alderley Park, both of which are located near Manchester in the UK, and at Watertown, MA, and Kalamazoo, MI, in the USA. With more than 1,500 partners, Cyprotex has a very strong customer network. Cyprotex reported H1 2016 revenues of £ 8.73 m (EUR 9.78 m) (H1 2015: £ 6.93 m (EUR 7.76 m)) with an underlying EBITDA of £ 2.34 m (EUR 2.62 m) (H1 2015: £ 1.10 m (EUR 1.23 m)).

Sharpening Evotec’s leadership role in drug discovery The acquisition strengthens Evotec’s high-end drug discovery platform and capabilities with access to the market’s most industrialised ADME-Tox platform and proven expertise in in vitro ADME screening, mechanistic and high-content toxicology screening and predictive modelling.

This perfectly augments Evotec’s drive for innovation efficiency in drug discovery by enabling its partners to make early informed decisions on a molecule’s suitability for further development. The Cyprotex platform can be leveraged in a high-throughput manner or to support integrated drug discovery projects.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “The ability to test or predict a molecule’s suitability as a drug at an early stage is critical in the drive to increase the efficiency of drug discovery.

The proposed acquisition of Cyprotex is a completely logical step to strengthen Evotec’s position as the world’s leading partner of choice for driving such efficiencies in drug discovery to the industry. The proven technology platform of Cyprotex and its expert and dedicated employees will be a strong addition to our best-in-class drug discovery platform and resources. We also expect that both organisations will leverage their extensive partner networks to identify further commercial synergies.”

Dr Werner Lanthaler, Chief Executive Officer of Evotec, added: “Our focus to make the most innovative and capital efficient drug discovery platform will be perfectly extended by Cyprotex. Given our strong performance over the last years, a very good outlook of our business into the coming years, and the commercial profile of Cyprotex we also feel very comfortable in using the cash on our strong balance sheet for this accretive acquisition. We are very much looking forward to welcoming the employees of Cyprotex within the Evotec Group after closing of the transaction.”

Categories: Innovation, Leadership


You Might Also Like
Read Full PostRead - Eye Icon
Leading Logistics Provider
Innovation
09/03/2021Leading Logistics Provider

The importance of a smooth supply chain cannot be ignored in this day and age. A good supply chain doesn’t just revolve around moving products from one place to another but building lasting relationships. This approach is why the team at Digistics has been n

Read Full PostRead - Eye Icon
Best Caribbean Restaurant – USA
Finance
01/07/2016Best Caribbean Restaurant – USA

Jamaican Grill is a chain of restaurants specialising in offering flavourful, Jamaican cuisine and excellence client service. Here at Jamaican Grill Restaurants is a totally unique BBQ concept that fuses the flavours of Jamaica, Guam and the Philippines.

Read Full PostRead - Eye Icon
People, Not Packages
Leadership
03/01/2018People, Not Packages

ICON Relocation have one of the most experienced management teams in the industry, with over 100 years of management experience in the relocation sector.

Read Full PostRead - Eye Icon
Kosmos Energy Makes Significant Gas Discovery Offshore Mauritania
Strategy
27/04/2015Kosmos Energy Makes Significant Gas Discovery Offshore Mauritania

Kosmos Energy announced today that the Tortue-1 exploration well, drilled to test the Tortue West prospect, which forms part of the Greater Tortue Complex, in Block C-8 offshore Mauritania has made a significant, play-opening gas discovery.

Read Full PostRead - Eye Icon
Ciena Acquisition of Certain TeraXion Assets
Finance
19/01/2016Ciena Acquisition of Certain TeraXion Assets

Ciena® Corporation, the network specialist, has entered into a definitive agreement with TeraXion Inc. to acquire its high-speed photonics components (HSPC) assets for approximately USD $32 million (CAD $46.6 million) in cash.

Read Full PostRead - Eye Icon
“Savvy Investor” an Instant Hit with Institutional Investors
Strategy
13/05/2015“Savvy Investor” an Instant Hit with Institutional Investors

A new professional network for pensions and investment professionals has proved an instant success, with 2000 registered members only two months after launch.

Read Full PostRead - Eye Icon
Most Outstanding Corporate Catering Services Provider 2021 – Australia
Leadership
10/05/2022Most Outstanding Corporate Catering Services Provider 2021 – Australia

We catch up with the founder of Catering HQ, Steve Sidd, to discuss with him the nitty gritty of operating in the modern catering industry. With so many catering and hospitality companies offering similar – if not the same – menu items and services, Cateri

Read Full PostRead - Eye Icon
This is a test
News
29/11/2021This is a test

this is a test of the link system to see how it copes with the link replacement being a full system with no-follow links in it.

Read Full PostRead - Eye Icon
The Role of Distracted Driving in U.S. Car Accidents
News
26/08/2024The Role of Distracted Driving in U.S. Car Accidents

The U.S. is experiencing a higher-than-normal spate of motor vehicle accidents.  Memphis, Tennesse was ranked #1 in a ConsumerAffairs report listing the U.S. cities with the most car crashes. Furthermore, Mississippi landed in the top spot in the states w



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow